Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lorbrena

- PMLiVE

Eliquis meets targets as long-term VTE therapy

Pfizer and BMS report positive phase III data for the Factor Xa inhibitor

- PMLiVE

Pfizer set for negative NICE decision on Inlyta

Institute's draft guidance doesn't recommend drug for advanced kidney cancer

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

- PMLiVE

Pfizer uses augmented reflection technology for mental health campaign

Teams up with Anxiety UK to raise awareness of GAD

- PMLiVE

Pfizer concludes NextWave acquisition

Sets company up to compete in the ADHD sector

Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer

Was VP global commercial disease area lead for pain at Pfizer

- PMLiVE

Eliquis cleared in EU for stroke prevention in AF

Follows last year’s approval for the prevention of VTE after surgery for BMS and Pfizer's drug

- PMLiVE

Cystic fibrosis group pledges $58m to Pfizer discovery programme

Pharma company forms public-private partnership with Cystic Fibrosis Foundation

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

- PMLiVE

Pfizer helps fund biotech venture from former researchers at closed Kent facility

Ziarco headed by former Pfizer chief scientific officer, allergy and respiratory research, Mike Yeadon

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links